ProQR Therapeutics N.V.
ProQR Therapeutics develops novel therapeutic medicines, focusing on products like AX-0810 for cholestatic diseases and AX-1412 for cardiovascular diseases. Other pipeline programs target Rett syndrome, NASH, obesity/Type 2 diabetes, and rare metabolic conditions. The company also develops the Axiomer RNA base-editing platform technology. ProQR has license agreements with several institutions and a collaboration with Eli Lilly for genetic disorder treatments.
Overview
Strengths
- Consistent growth: revenue has compounded at 85.8% a year over 4 years, rising in 3 of them.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 4.8% in 5 of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 5 of the last 6 years.
- Unstable profitability: operating margin ranged from -4,285% to -161% over the last 5 years, with operating losses in 5 of them.
Key Financial Data